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Abstract
Hepatitis B (HBV) infection is endemic in Viet Nam, with up to 8.4 million individuals estimated to be chronically infected.
We describe results of a large, multicentre seroepidemiological and molecular study of the prevalence of HBV infection and
blood-borne viral coinfections in Viet Nam. Individuals with varying risk factors for infection (n=8654) were recruited from
five centres; Ha Noi, Hai Phong, Da Nang, Khanh Hoa and Can Tho. A mean prevalence rate of 10.7% was observed and
levels of HBsAg were significantly higher in injecting drug users (IDUs) (17.4%, n=174/1000) and dialysis patients (14.3%,
n=82/575) than in lower-risk groups (9.4%; p,0.001). Coinfection with HIV was seen in 28% of HBV-infected IDUs (n=49/
174) and 15.2% of commercial sex workers (CSWs; n=15/99). HCV infection was present in 89.8% of the HBV-HIV coinfected
IDUs (n=44/49) and 40% of HBV-HIV coinfected CSWs (n=16/40). Anti-HDV was detected in 10.7% (n=34/318) of HBsAg
positive individuals. Phylogenetic analysis of HBV S gene (n=187) showed a predominance of genotype B4 (82.6%);
genotypes C1 (14.6%), B2 (2.7%) and C5 (0.5%) were also identified. The precore mutation G1896A was identified in 35% of
all specimens, and was more frequently observed in genotype B (41%) than genotype C (3%; p,0.0001). In the
immunodominant ‘a’ region of the surface gene, point mutations were identified in 31% (n=58/187) of sequences, and
2.2% (n=4/187) and 5.3% (n=10/187) specimens contained the major vaccine escape mutations G145A/R and P120L/Q/S/T,
respectively. 368 HBsAg positive individuals were genotyped for the IL28B SNP rs12979860 and no significant association
between the IL28B SNP and clearance of HBsAg, HBV viral load or HBeAg was observed. This study confirms the high
prevalence of HBV infection in Viet Nam and also highlights the significant levels of blood-borne virus coinfections, which
have important implications for hepatitis-related morbidity and development of effective management strategies.
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Introduction
The World Health Organisation (WHO) has estimated that
over 350 million people worldwide are chronically infected with
Hepatitis B virus (HBV) which results in approximately 600,000
HBV related deaths each year, primarily from cirrhosis and
hepatocellular carcinoma (HCC) [1]. In geographic regions with
low HBV endemicity, the virus is normally acquired in adulthood
through horizontal routes of transmission, which include high risk
sexual behaviour, receipt of blood products, blood-blood contact
or injecting drug use. In contrast, in countries with intermediate
and high endemicity, HBV is primarily acquired by vertical
transmission perinatally or early in childhood [2,3].
There are approximately 8.4 million individuals chronically
infected with HBV in Viet Nam and it was estimated that in 2005
this resulted in 23,300 HBV-related mortalities [4]. Previous
reports of HBV surface antigen (HBsAg) prevalence have
suggested levels as high as 15–20% in the general population
[5–13]; with reported prevalences in neonates, children and
adolescents of 12%, 18% and 20%, respectively [10]. Universal
HBV vaccination was introduced in Viet Nam in 2003; however,
despite this, mathematical models have predicted that Viet Nam in
the future faces an enormous burden of HBV-related liver disease
[4].
Eight HBV genotypes (designated A through H) and several
subgenotypes have been identified to date, and these have distinct
geographic distributions [14]. In addition, a complex recombinant
of genotypes C, A and G, first described in Viet Nam in 2000 [15],
has been proposed to be a new genotype designated ‘‘I’’ [16].
However this remains controversial as the mean genetic di-
vergence of the Vietnamese HBV A/C/G recombinant is ,8%
from genotype C across the entire genome and is thus considered
as having arisen from intragenotypic, not intergenotypic, di-
vergence [17]. This variant was subsequently identified in Laos
[18], China [19,20], India [21] and in emigrants and children
adopted from Viet Nam and living in France and Canada [22,23].
An additional genotype ‘‘J’’ has also been proposed for a virus
isolated from one Japanese male [24].
Human Immunodeficiency Virus (HIV) and Hepatitis C virus
(HCV) coinfections in individuals with chronic HBV infection are
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39027increasingly common due to shared routes of transmission.
Globally, it is estimated that 4 million chronically HBV-infected
individuals are coinfected with HIV [25]. Limited information is
available on the prevalence of coinfections in Southeast Asia
because of a lack of routine screening. Zhou et al. reported a large
serosurvey of HIV, HBV and HCV infection among injecting
drug users (IDUs) along the Chinese-Myanmar border and
indentified 20% HIV-HBV coinfections and 11% HIV-HBV
coinfections in Chinese and Burmese IDUs, respectively, with
a comparable prevalence of HIV-HBV-HCV triple infections
(19% and 10%, respectively) in each population [26]. Unlike
HBV, the HIV epidemic in Viet Nam is concentrated in high risk
groups, such as IDUs, commercial sex workers (CSWs) and men
who have sex with men (MSM) [27,28]. A study from Hai Phong
in Northern Viet Nam reported a HBsAg prevalence of 10.3% in
HIV-infected individuals [13]. In industrialised countries, the
introduction of highly active antiretroviral therapy (HAART) has
lead to a significant decline in deaths attributable to HIV;
however, liver disease has since emerged as a leading cause of
morbidity and mortality in HIV infected individuals coinfected
with HBV and HCV [29,30]. Management of HBV in HIV-
infected individuals is also complicated by the emergence of drug
resistant viruses and HAART-associated hepatotoxicity. The use
of antiretroviral drugs may result in the emergence of cross-
resistance mutations in the HBV pol gene. Specifically, it has been
reported, that in HIV-HBV coinfected patients treated with
lamivudine, resistance mutations within the YMDD motif in the
HBV polymerase reverse transcriptase (RT) domain occur at a rate
of approximately 25% per year, compared to approximately 16%
in HBV monoinfected patients [31,32].
Hepatitis Delta virus (HDV) is a small, defective RNA virus that
utilises HBsAg to produce infectious particles and can only
replicate in individuals already infected with HBV [33,34].
Globally, an estimated 18 million (ca. 5%) of the 350 million
chronic HBV carriers have serological evidence of prior exposure
to HDV and HBV-HDV coinfection has been reported to have
a more severe clinical course than HBV monoinfected individuals
[35–39]. The incidence of HDV infection appears to be de-
creasing worldwide due to the impact of HBV vaccination
programmes. Typically, HDV prevalence is highest in regions
where HBV is endemic [34]; however, previous studies have
reported very low or undetectable levels of HDV infection in Viet
Nam [11,40].
Several viral factors, including genotype and specific viral
mutations, have been documented to influence the clinical
outcome of HBV infection. Among these, HBV genotype is not
only a predictor of clinical outcome but has also been associated
with response to interferon treatment [41]. Although there is a well
established predominance of HBV genotypes B and C in
Southeast Asia, including Viet Nam, previous reports suggest that
there may be significant genetic heterogeneity at the subgenotype
level; HBV subgenotypes B2, B4, C1 and C5 have been reported
in Viet Nam with subgenotypes B4 and C1 predominating
[13,40,42–46]. In addition, the putative HBV genotype I has been
reported to account for 1% of circulating virus in Viet Nam [46].
Emerging data has shown that HBV viral load and naturally
occurring mutant strains may be closely associated with pro-
gression to severe liver disease [41]. For example, genotype C has
a higher frequency of mutations in the basal core promoter (BCP)
and deletions in the preS region of the genome and is associated
with higher viral loads than genotype B [41]. HBV genotype C
infection has been associated with a decreased rate of response to
interferon-a therapy compared with genotype B [41]. Selection
pressures including vaccination, antiviral therapy and host
immune response may result in the emergence of viral variants
which are associated with progression to more severe liver disease
[47].
Recently, genome wide association studies have highlighted the
impact of host genetics on the outcome and impact of viral
infection. Genetic variation adjacent to the type III interferon
gene, interleukin-28B (IL28B) on chromosome 19q13 is strongly
associated with both treatment-induced and natural clearance of
HCV; in contrast, the effect on HBV infection is unclear [48–50].
However, recent studies have reported an association between the
IL28B locus and response to interferon- a therapy [51,52].
Here, we describe the results of a large-scale, national study,
estimating the prevalence of hepatitis B virus and blood-borne
virus coinfections in different regions and different risk groups in
Viet Nam.
Materials and Methods
Ethics Statement
Ethical approval for the study was obtained from the National
Institute of Hygiene and Epidemiology (NIHE) in Ha Noi. All
specimens and survey information were obtained with informed
written consent and subsequently anonymised.
The study is part of the Ireland Viet Nam Blood-Borne Virus
Initiative (IVVI) which is a partnership between the National
Virus Reference Laboratory (NVRL) in Dublin, Ireland and the
National Institute of Hygiene and Epidemiology (NIHE) in Ha
Noi, Viet Nam. In all, 8654 specimens were serologically tested for
HIV, HBV and HCV infection. The study involved eight
population groups including commercial sex workers (CSWs),
injecting drug users (IDUs), blood donors, military recruits,
pregnant women, dialysis patients, elective surgery patients and
recipients of multiple blood transfusions. Paired serum and plasma
specimens were collected in 2008 and 2009, along with detailed
demographic information, from five centres throughout Viet Nam:
Ha Noi (n=1750) and Hai Phong (n=1750) in the North, Da
Nang (n=1750) in the Central region and Khanh Hoa (n=1725)
and Can Tho (n=1679) in the South.
Viral Serology
All specimens were tested using commercially available EIAs for
HBsAg using Murex HBsAg version 3 (Abbott Laboratories, IL,
USA), for HIV antibody and antigen using the Genscreen HIV
Ab-Ag serological screening kit (Bio-Rad Laboratories, CA, USA)
and for HCV using the MONOLISA Ag/Ab HCV Ultra (Bio-
Rad Laboratories, CA, USA). A representative subset (n=372) of
HBsAg positive specimens, collected from high and low risk groups
in the five study sites, were chosen for additional serological
markers and detailed molecular analysis. Specimens were tested
for the presence of HBeAg (n=356) and, if negative, for anti-HBe
(n=208) using ETI-EBK-PLUS (HBeAg) and ETI-AB-EBK
PLUS (anti-HBe; DiaSorin, Saluggia, Italy). 276 samples (in-
cluding all HBeAg positive samples) were tested for HBc IgM
using ETI-CORE-IgMK PLUS (DiaSorin, Saluggia, Italy). A
selection of 110 HBsAg negative samples were screened for HBV
total core (anti-HBc) using the MONOLISA anti-HBc Assay (Bio-
Rad Laboratories, CA, USA). In addition specimens (n=319)
were tested for evidence of infection with delta virus using ETI-
AB-Delta-K2 (anti-HDV) and positives were tested for IgM anti-
HDV with ETI-DELTAK-IGMK-2 assay (DiaSorin, Saluggia,
Italy; n=319).
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Nucleic acids were extracted from 200 ml of plasma from
HBsAg positive (n=376) and negative specimens (n=110), using
the QIAamp DNA Blood Mini Kit (Qiagen, Crawley, UK) as per
the manufacturer’s instructions, with a final elution in 50 ml. l
phage DNA (25 pg/sample) was added to the lysis buffer during
the extraction as an exogenous internal control for the viral load
assay [53].
HBV viral load (VL) was determined using an ‘‘in-house’’
quantitative real-time polymerase chain reaction (qPCR) with
serial dilutions of a plasmid-derived HBV DNA standard were
used to prepare the standard curve and l phage DNA co-
amplified as an internal control. The PCR reaction was performed
with 10 ml of extracted DNA in a 25 ml total reaction volume with
the Platinum qPCR Supermix kit (Invitrogen
TM Life Technolo-
gies, Paisley, UK), and 0.4 mM oligonucleotide primers and
Figure 1. Map of Viet Nam Depicting the Prevalence of HBsAg in 5 Regions. The map depicts the percentage HBsAg positives in Ha Noi, Hai
Phong, Da Nang, Khanh Hoa and Can Tho. To the right is a graph depicting the prevalence of HBsAg in each of the study groups in the 5 study sites
in Viet Nam.
doi:10.1371/journal.pone.0039027.g001
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gene [54]. The reaction was amplified on an ABI 7500 FAST real-
time platform (Applied Biosystems) with an initial 2 min in-
cubation at 50uC, followed by 10 min at 95uC and 45 cycles of
95uC for 15 s and 60uC for 1 min. The assay was calibrated
against the WHO 2
nd International Reference Standard for HBV
DNA (NIBSC: 97/750) and validated with a 95% limit of
quantitation of 500 IU/ml plasma (2.69 log10 IU/ml) and a linear
dynamic range of 5E2–5.4E9 IU/ml (2.69–9.73 log10 IU/ml).
The assay was validated to ensure high concordance with
commercially available HBV DNA platforms, giving R
2 values
of 0.91 and 0.96 when compared to Siemens VERSANT bDNA
3.0 and Roche COBASH Ampliprep-COBAS TaqManH HBV
quantitiative assays, respectively.
HBV genotype and mutation analyses were determined for
specimens with detectable HBV DNA using a hemi-nested PCR
targeting a 1.1 kb fragment of the pol gene, incorporating partial
preS1 and the entire preS2 and S genes (fragment B), and a nested
PCR targeting the basal core promoter/precore region (fragment
D) [55,56] (see Table S1 for all oligonucleotide primers employed
in this study). In a subset of specimens (n=28) the two additional
flanking fragments A and C were amplified to obtain whole-
genome sequences. Assays for fragments A, B and C were
modified from previously published studies [55,57,58]. For
fragment B, 5 ml of extracted DNA was used with Expand High
Fidelity PCR system (Roche Applied Sciences, Mannheim,
Germany) in both rounds of a hemi-nested PCR as follows:
primers P4mod and P5mod – with a 2 min initial denaturation at
94uC, followed by 10 cycles of 94uC for 15 s, 60uC for 30 s and
72uC for 60 s and a further 20 cycles of 94uC for 15 s, 50uC for
30 s and 72uC for 60 s and a final extension step of 7 min at 72uC.
The PCR product was further amplified in a hemi-nested PCR
with primers P5mod and P6 using the same cycling conditions
with 30 cycles instead of 20 cycles for the second amplification
phase. The products were visualised on a 1% TAE agarose gel
with 0.01% (v/v) of SYBR safe dye (Invitrogen, Paisely, UK). For
whole-genome amplification: fragment C amplification was
performed as for fragment B but with primers POLF1 and P5W
in the first round and POLF2 and P4WRS in the second round.
Finally, fragment A PCR employed primers P1 and P2 in the first
round and P1 and P3 in the second round, with the same cycling
conditions as for fragment B except for an annealing temperature
of 55uC for the 20 cycles/30 cycles in round 1 and round 2,
respectively.
The limit of detection of the fragment B (pol gene) assay was
approximately 2.5 Log10 IU/ml. Nucleotide sequence was
obtained for 194 specimens, although, a small subset (5.8%,
n=11) showed evidence of mixed infection in the preS region but
not in the S gene and were thus included in the S gene mutation
analysis but omitted from phylogenetic analysis. Consequently,
187 specimens were analysed for mutations in the S gene and 178
specimens were subgenotyped using phylogenetic methods.
Genbank accession numbers for the pol gene sequences are
JQ281112-JQ281258 and JQ281468-JQ281471.
Fragment D, encompassing the precore region, was amplified
using the Qiagen HotStar Platinum TaqH (Qiagen, Crawley, UK)
in both rounds of a nested PCR with the following cycling
conditions for both rounds: denaturation at 95uC for 15 mins,
45 cycles of 94uC for 60 s, 50uC for 45 s an 72uC for 45 s and
a final extension at 72uC for 10 mins [56]. Every assay contained
negative and reagent only controls. The precore fragment was
successfully amplified in 236 specimens; Genbank accession
numbers JQ281259-JQ281467.
TaqMan 59 Nuclease Allelic Discrimination Assay
Genomic DNA from serum or plasma specimens from the
virological analysis were genotyped for the IL28B SNP rs12979860
(n=368) using the ABI 26mastermix kit (Applied Biosystems) on
the TaqMan 7300 platform (Applied Biosystems) as described
previously [59].
Statistical Analysis
Data is presented here as means 6 standard deviation and
ranges. Continuous variables, such as viral load, were compared
between populations using the Student’s t-test. Categorical data
were analysed using Chi-squared and odds ratio tests. Associations
between IL28B and HBeAg, confounding for age and sex, were
examined using a linear regression analysis and SPSS software
Figure 2. Percentage of Blood-Borne Viral Coinfections in HBsAg Positive Intravenous Drug Users. ‘‘A’’ represents the proportion of
HBsAg positive IDUs (n=174) also testing positive for HIV Ab/Ag and HCV Ab/Ag (n=98) and ‘‘B’’ represents the proportion of HBsAg positive IDUs
(n=78) testing positive for HDV (n=20).
doi:10.1371/journal.pone.0039027.g002
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cant.
Sequence Analysis and Phylogenetic Characterisation
For nucleotide sequence reactions, unincorporated primers and
dNTPs were removed from amplified products using Exo-SAP IT
(Affymetrix, Cleveland, USA), and subsequently sequenced bi-
directionally on an ABI 3730 sequencing platform using primers
detailed in Table S1.
In total, 178 fragments of 1,070 nucleotides of the HBV pol gene
were compared with reference sequences available from Genbank
representing each genotype and all subgenotypes of B and C. 236
sequences from the basal core promoter/precore fragment were
analysed for mutations. The genotype of the 236 precore
fragments was determined using online tools and BLAST analysis.
Lasergene version 8 (DNASTAR, Madison, WI, USA) was used
for contiguous sequence assembly [60], and the sequences were
aligned using ClustalW [61], implemented in Bioedit version 7.05
[62]. A phylogenetic tree was constructed using the neighbour
joining distance method under a Kimura-2-parameter model of
evolution in PAUP* version 4.0 beta10 [63]. Statistical support for
the topology of the trees was provided by 1000 bootstrap
replicates. Reference sequences used represented all currently
assigned genotypes of HBV, with the woolly monkey HBV strain
(Genbank accession number: AF046996) used as an out-group.
Numbering of HBV nucleotides starts at the EcoRI cleavage site or
at homologous sites, if the EcoRI site is absent. HBV pol gene
sequences were also analysed using the online genotyping tool
Geno2Pheno (http://hbv.bioinf.mpi-inf.mpg.de/index.php)
which compares the query sequence to reference sequences to
identify known mutations associated with resistance to lamivudine,
adefovir, entecavir, tenofovir and telbivudine, and with immune
escape.
Results
Prevalence of HBV in Viet Nam
In total, 8654 specimens collected from eight well defined
population groups in 5 different geographical regions were
analysed for evidence of HIV, HBV and HCV infection. Of
these, 10.7% (n=925) tested positive for HBsAg, with a prevalence
ranging from 9.4% in the lower risk groups (pregnant women,
military recruits, patients admitted for elective surgery and blood
donors) to a significantly elevated 17.4% (p,0.0001) in the IDU
group (Figure 1). Notably, there was a high prevalence in the renal
dialysis groups throughout the country (14.3%) and this was
significantly higher than in the lower risk groups (p,0.0001).
10% of a subset of HBsAg positive samples further analysed
tested positive for HBcIgM (n=27/272), although many were
weakly positive. Fifty percent of 110 HBsAg negative specimens,
collected from all patient groups, had detectable anti-HBc
demonstrating a significant number of resolved HBV infections.
HBV DNA was undetectable in the 110 HBsAg negative
specimens.
Figure 3. Phylogenetic Analysis of 1070 nt Region of the HBV Pol Gene of Specimens Identified in the IVVI Study. The taxons and
branches of Vietnamese specimens whose sequences were identified in this study are coloured by sample location from Ha Noi (red), Hai Phong
(orange), Da Nang (purple), Khanh Hoa (blue) and Can Tho (green). Sequence taxons are coded by population group including intravenous drug
users (IDU), sex workers (SW), dialysis patients (DIAL), multiply transfused patients (MTF), military recruits (MIL), pregnant women (PRE), blood donors
(BD) and elective surgery patients (SUR). Figure 2A represents a phylogenetic analysis of genotype B sequences, including 152 sequences from HBV
subtype B described in this study, with 64 reference sequences (labelled with their Genbank accession numbers and country of isolation). Branches of
reference sequences from groups A, C, D, E, F, G and H are collapsed. The newly described putative subgenotype B6–B9 sequences were included and
branches have been collapsed. Figure 2B represents 26 sequences from HBV subtype C described in this study, with 73 reference sequences. Brackets
denote the subgenotypes identified in this study and the number of IVVI sequences in these groups. Genbank accession numbers for the study
sequences are JQ281112–JQ281258 and JQ281468–JQ281471.
doi:10.1371/journal.pone.0039027.g003
Table 1. Correlation of HBV Viral Load and Genotype in HBeAg Positive and Negative Individuals (n=217).
HBeAg positive HBeAg negative p–value Statistical Method
n = 87 127
Mean Age (yrs 6 SD, range) 24.167.4 (16–55) 32.7613.3 (18–79) ,0.0001 2 tailed t test
% Male 58.6% 42.5% 0.02 x
2
HBV DNA (Log10 IU/ml)
Mean Viral Load 7.5861.34 (2.45–8.9) 3.3261.65 (0.15–8.36) ,0.0001 2 tailed t test
DNA undetectable (%) 4.6% 19.7% 0.002 x
2
#2,000 2.3% 44.9% ,0.0001 x
2
2,001–20,000 2.3% 20.5% ,0.0001 x
2
20,001–200,000 1.1% 5.5% 0.098 x
2
200,001–2,000,000 8.0% 4.7% 0.499 x
2
.2,000,001 81.6% 4.7% ,0.0001 x
2
HBV Genotype n=64 n=82
B 79.7% 87.8% 0.285 x
2
C 14.1% 8.5%
All individuals in this cohort tested positive for HBsAg and serologically negative for HIV, HCV and HDV.
doi:10.1371/journal.pone.0039027.t001
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In total, 58% of HBsAg positive IDUs and 22% of HBsAg
positive CSWs had evidence of infection with at least one other
blood-borne virus (Figure 2). Of 273 HBsAg positive specimens
identified in the high risk study groups, coinfection with HIV was
demonstrated in 28% of IDUs (n=49/174; Figure 2) and 15.2%
of CSWs (n=15/99). Furthermore, HCV Ab/Ag was demon-
strated in 89.8% of the HIV-HBV coinfections in IDUs (n=44/
49) and in 40% in CSW (n=16/40). Evaluation of HBV-HIV
coinfected patients revealed no significant differences in the mean
HBV viral load or percentage of HBeAg negatives, compared to
HBV monoinfected individuals (5.19 vs 5.23 Log10 IU/ml; 60% vs
59%).
10.7% (n=34/318) of HBsAg positive specimens were positive
for anti-HDV total antibody. The highest prevalence of total
antibody was identified in IDUs (25.6%, n=20/78; Figure 2),
followed by military recruits (17.8%, n=8/45), CSWs (8.8%,
n=5/57) and in a single dialysis patient (2.4%, n=1/41). Anti-
HDV total was not identified in any of the remaining low risk
groups. Of note, 17.9% (n=14/78) of HBSAg positive IDUs were
quadruply infected with HBV-HIV-HCV-HDV. In HBV-HDV
infected individuals, the mean HBV viral load was lower (4.2
Log10 IU/ml) and the seroconversion of HBeAg was higher (71%)
when compared to HBV monoinfected individuals (5.2 Log10 IU/
ml, 59% HBeAg negative, p=0.194). 33% of 21 delta virus total
antibody positive specimens were HDV IgM positive, all with low
(,2.5 Log10 IU/ml) or undetectable HBV viral load.
Molecular Analysis
73% (n=273/376) of HBsAg specimens screened had detect-
able HBV viral load and the mean viral load was 5.2162.56 Log10
IU/ml. Phylogenetic analysis showed that all individuals were
infected with either genotype B or genotype C, and four distinct
subgenotypes were identified (Figure 3). HBV subgenotype B4
(82.6%) predominated. Other genotypes detected included B2
(2.7%), C1 (14.6%) and C5 (0.5%). The newly described HBV
putative ‘‘genotype I’’ was not detected.
The presence of HBeAg correlated significantly with viral load
and the mean viral load in HBeAg positive samples was 7.58 Log10
IU/ml compared to 3.32 Log10 IU/ml in HBeAg negatives
(p,0.0001; Table 1). Patients with HBeAg negative infection were
on average significantly older (mean 32.7 vs 24.1 years; p,0.0001),
had significantly lower or undetectable HBV DNA levels (DNA
detected 65% vs 7%; p,0.01), and were more likely to be infected
with genotype B (87.8% vs 79.7%; p=0.29) than those who had
HBeAg positive infection (Table 1).
Genetic Variation within the Surface Antigen Region
187 HBV sequences were analysed for the presence of deletions
and mutations in the surface gene. One or more point mutations
were identified within the immunodominant ‘a’ region in 31%
Figure 4. Mutations in the Basal Core Promoter and PreCore Regions of the HBV Genome in Genotype B and C Viruses. The precore
stop mutation G1896A was identified in 35% (n=82/236) of all samples and varied significantly by viral genotype, with a higher occurrence in
genotype B (41%) compared to Genotype C (3%) (p,0.001). In contrast, the basal core promoter mutations A1762T and G1764A were detected more
frequently in genotype C at 49% and 51% respectively, compared to only 22% and 18% in genotype B (p,0.0001). The mutation T1858C was
identified only in genotype C viruses.
doi:10.1371/journal.pone.0039027.g004
Table 2. Association of IL28B Genetic Variation at rs12979860 with HBV Viral Load and Serology.
CC CT + TT p–value OR (95% CI)
HBsAg positive, n=214 85.0 15.0 0.498 1.377 (0.5444–3.488)
HBV negative, n=53 88.7 11.3
HBeAg positive, n=87 92.0 8.0 0.059 2.472 (0.965–6.333)
HBeAg negative, n=127 80.3 19.7
HBV DNA #2610
4 Log10 IU/ml, n=120 82.5 17.5 0.238 1.601 (0.729–3.514)
HBV DNA.2610
4 Log10 IU/ml, n=94 88.3 11.7
All individuals in this cohort were serologically negative for HIV, HCV and HDV.
doi:10.1371/journal.pone.0039027.t002
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immune escape were identified in 23.5% (n=45/187) samples
and included the following residues Y100C (n=6), T118K (n=1),
P120L/Q/S/T (n=10), T123A/N (n=2), I126N/S (n=8),
P127S (n=2), Q129R (n=2), G130D/N/R (n=1), T131I
(n=4), M133L/T (n=18), G144E (n=1) and G145A/R (n=4).
Sixty-four specimens had mutations in the T cell epitope
(including N40N/S, L42L/P, G44D/E/G, A45T, P46H,
T47A/E/K/T). In the preS2 region, 5.5% of specimens had
a point mutation in the start codon which changed the amino acid
to I (3.3%), V (1.7%) or T (0.55%), and 5.3% had a mutation at
F22L with either a single or dual point mutation at this site.
Deletions were found in 5% (n=9/187) of S gene sequences,
ranging from 6 to 57 nucleotides in length. One sample had two
deletions of 9 and 57 nucleotides in different regions of the preS1
and preS2 genes, and another sample had a deletion which
involved the preS2 start codon. The majority of these S gene
deletions were identified in the genomes of high risk IDUs and
CSWs (n=8). No significant difference in history of vaccination
was identified in individuals whose sequences contained mutations
associated with immune escape (18.6%, n=8/42) compared to
sequences that did not (24%, n=35/99; p=0.431).
Drug Resistance Mutations
Of 376 HBsAg positive specimens, only 19 (5%) were from
individuals who reported having received treatment. All were
coinfected with HIV and were receiving lamivudine as a compo-
nent of HAART. 78.9% (n=15/19) of these individuals had
undetectable HBV viral loads and, of the 4 patients on HAART
with a detectable HBV viral load, one – a HIV/HBV/HCV
coinfected IDU – had drug resistance associated mutations,
L180M and M204V in the pol gene conferring resistance to
lamivudine and possible resistance to telbivudine. Analysis of other
HBsAg positive and HIV Ag/Ab negative specimens (n=165) did
not reveal the presence of drug resistance associated mutations.
Precore Mutations
Analysis of mutations in the basal core promoter and precore
regions showed significant variation with genotype. 35% of all
specimens had the precore stop mutation G1896A which
abrogates HBeAg production; however, this was detected in
41% of genotype B compared to only 3% of genotype C viruses
(p,0.0001; Figure 4). In contrast, the basal core promoter
mutations A1762T and G1764A were detected more frequently
in genotype C at 49% and 51% respectively, compared to only
22% and 18% in genotype B (p,0.0001). 1858C was detected only
in genotype C viruses (n=36). Evaluation of fragments for which
there was an available corresponding S gene sequence also
identified a difference in mutational patterns at the subgenotype
level: B2 viruses compared to B4 for both G1896A (20%, n=1/5
vs 40.2%, n=53/132) and A1762T/G1764A (40%, n=2/5 vs
19.7%, n=26/132). We also identified a 21 bp deletion in the
basal core promoter region of one sequence from a 55 year-old
multi-transfused patient in Khanh Hoa (JQ281259).
Genetic Variability at the IL28B Locus
HBsAg positive individuals (n=368) from the five centres were
genotyped for the IL28B SNP rs12979860 and the C allele
frequency was found to be 93%. Overall, 86.41% (n=318) were
major homozygotes [CC], 13.04% (n=48) were heterozygotes
[CT] and 0.54% (n=2) were minor homozygotes [TT]. A
comparison of all monoinfected HBsAg positive individuals
(n=214) with individuals with resolved infection (i.e. HBsAg
negative, HBc total positive and HBV DNA negative; n=53)
demonstrated no significant difference in genotype frequency
(p=0.50). Furthermore, HBV viral load was not significantly
influenced by rs12979860 genotype (p=0.24; Table 2) and
multivariate regression analysis confounding for age and sex did
not reveal a statistically significant association between the IL28B
SNP and HBeAg positive and negative individuals (p=0.06).
Discussion
It is now clear that, as in many countries in Southeast Asia,
HBV is endemic in Viet Nam and contributes to a significant
burden of liver disease in the country. The present report provides
one of the most comprehensive studies of HBV in Viet Nam to
date, involving distinct geographical regions and populations with
different risk factors for infection. The clinical outcome of HBV
infection and the response to treatment and vaccination is
influenced by a number of factors including coinfection with
other blood-borne viruses, viral genotype, virus specific mutations
in the pre-core and basal core promoter regions of the genome and
a number of host factors. The present study has involved
molecular analysis to analyse viral load, viral genotype and core
and pre-core mutants. In addition our studies have examined
coinfections with other blood-borne viruses including HIV, HCV
and HDV – all of which would be expected to impact on HBV
pathogenesis, and on the overall development and progression of
liver disease.
The results of this study have confirmed the high level of
endemicity of HBV in Viet Nam. As expected, levels of HBsAg are
highest in the higher risk groups such as IDUs and CSWs,
however, levels were also elevated in the dialysis cohorts from each
region. Core IgM was detected in 27 samples and, while this may
be suggestive of acute infection, confirmation is difficult due to the
possibility of persistent detectable IgM in chronic infection.
Serological analysis of HBsAg negative samples in eight groups
in the study also demonstrated that some 50% of individuals tested
had evidence of resolved HBV infection.
Our study also identified a very high prevalence of blood-borne
viral coinfections. As expected, this was most evident in the IDU
cohort, where serological analysis revealed that 53%, 28% and
26% of hepatitis B infected participants were coinfected with
HCV, HIV and HDV, respectively. In fact, a significant pro-
portion of these individuals had either triple or quadruple
infections, with 18% of hepatitis B infected IDU patients infected
with HIV, HCV and HDV. The prevalence of coinfection in the
sex worker cohort, although marked, was less significant with 10%,
15% and 9% of the hepatitis B infected participants also infected
with HCV, HIV and HDV, respectively. In contrast, there was
little evidence of coinfections in the hepatitis B infected
participants from lower risk groups.
High levels of HIV-HBV coinfection have significant implica-
tions for the introduction of HAART for HIV treatment. Our
results suggest that it would be advisable that all HIV infected
individuals in Viet Nam, if possible, should be screened for active
HBV infection. A recent study from the US has shown that
patients with chronic HBV, as defined by HBsAg positivity, had
a much higher risk for developing the composite outcome of an
AIDS-defining illness or death compared to individuals who were
HBV negative [64]. Studies from South Africa have indicated that
lamivudine, when employed as a sole HBV active drug in
a HAART regimen, may not reliably suppress HBV replication
[65]. As such, at least two drugs with anti-HBV activity (tenofovir
plus lamivudine or plus emtricitabine) should be employed in the
setting of HIV-HBV coinfection [66]. Indeed, tenofovir-based
regimens are now being introduced as front line therapy of HIV
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development of HBV resistance which can occur when single
agents are employed, as we have found in the present study.
Monitoring of such treatment should also, if possible be
accompanied by measurement of both HIV and HBV viral loads
to assess the efficacy of treatment. In addition to specific
treatments, efforts should be enhanced to provide HBV vaccina-
tion to individuals with or at risk of HIV infection.
The present study also demonstrated significant levels of HDV
infection. The overall prevalence across the cohorts of 10.7%
(patients infected with HBV coinfected with HDV) is in a marked
contrast to previous reports in Viet Nam, where rates of
approximately 1% were described [11,40]. The variation in
HBV-HDV coinfection rates across the cohorts could be stratified
between high and low risk exposure groups, with the vast majority
of HDV infections occurring in the IDU and CSW cohorts. The
difference between this and previous studies most likely reflects the
inclusion of these defined high risk cohorts from urban centres.
Molecular analysis of HBV DNA in HBV-HDV coinfected
participants showed a significant reduction in detectable HBV
viral load and a higher rate of e antigen negativity, when
compared to the HBV monoinfected cohort. Our findings suggest
that levels of HDV exposure in Viet Nam are significantly higher
than previously recognised and that the burden of liver disease
associated with HBV-HDV infection may be more substantial
than previously thought.
Molecular studies demonstrated that HBV genotypes B4 and
C1 predominated, but there were also smaller levels of B2 and C5.
In agreement with a previous study, we did not identify the
putative genotype I, suggesting that this recombinant remains rare
in Viet Nam [46]. The lack of proofreading ability of the HBV
polymerase, together with the high viral titre in active HBV
infection, results in a high mutation rate during virus replication.
Genetic mutations and deletions in the pre-S and basal core
promoter regions of the HBV genome including T1753V,
A1762T, G1764A, and C1766T have been associated with more
severe liver disease and the development of HCC [67,68]. The
basal core promoter mutations 1762T/W and 1764A/R were
detected in 26% and 24% of specimens, respectively. Previous
reports of heterogeneity in the BCP/PC region of HBV in Viet
Nam identified prevalence rates of up to 32% 1753C/A, 68%
1762T/1764A, 70% 1858C and 12% 1896A in genotype C
viruses compared to 28% 1762T/1764A, 0% 1858C and 34%
1896A in genotype B [69,70]. We identified the precore stop
mutation G1896A in 35% (n=82/236) of all samples, and this
varied significantly with viral genotype, with a higher incidence in
genotype B compared to genotype C, which is in agreement with
previous studies [69,70]. Contrastingly, the basal core promoter
mutations 1762T and 1764A were detected more frequently in
genotype C than in genotype B, and 1858C was identified only in
genotype C viruses. Although the numbers were too low to reach
statistical significance, we also identified a difference in the
G1896A and A1762T/G1764A mutations at the subgenotype
level, which has also been previously reported [71].
Of increasing concern is the emergence of mutations in epitopes
of the HBV S gene which have been associated with immune
escape [47]. As the HBV pol gene overlaps the S gene, mutations in
the pol gene could result in non-synonymous mutations in the
corresponding open reading frame. Thus, mutational pressure on
the pol gene may potentially alter the antigenic characteristics of
the surface protein, which could in turn alter vaccine efficacy and
affect serological diagnostic assays targeting this region. We have
found that 31% of our sequences contained mutations in the
immunodominant region of the S gene and have identified a high
number of potential immune escape mutants. Of particular note,
2.2% of sequences analysed contained the major vaccine escape
mutation G145A as a dominant or as a mixed population. Analysis
of the preS region demonstrated that a total of 5% of specimens
had preS deletions (primarily identified in high risk individuals),
5.5% contained amino acid mutations in the start codon of the
preS2 and 5.3% had an F22L mutation in the preS2, all of which
have been significantly associated with the development of HCC
[68].
The role of host immunogenetics in influencing the rates of
spontaneous HBV clearance and the development of persistent
infection is poorly understood. IL28B genetic variants have
previously been associated with natural and therapy-associated
clearance of HCV [48,72–74]. In contrast, recent studies have
found no significant differences in IL28B allele frequencies
between individuals who spontaneously clear or those who develop
a persistent HBV infection [49,50]. Interestingly, a Chinese study
by Li and colleagues demonstrated an association between the
rs12979860 CC genotype (associated with a favourable HCV
response to therapy and higher natural clearance rates) with
elevated IL28B protein levels in serum and with lower HBV viral
loads (,10
5 copies/ml) compared to both CT and TT genotypes.
IL28B genotype has also recently been implicated in rates of
HBeAg seroconversion (appearance of anti-HBe) following in-
terferon-a treatment and also HBsAg clearance after follow up,
although the latter effect was modest and further studies are
required to corroborate these findings [51,52]. In our study,
comprising untreated, HBV monoinfected Vietnamese individu-
als, we did not observe a significant association between the IL28B
genotype and clearance of HBsAg or variation in HBV DNA
levels. Although we noted an association between Il28B and
HBeAg status, this did not reach statistical significance which may
be due to the low T allele frequency (7%) in Viet Nam. Our
analysis does not exclude a role for this locus in influencing HBV
viral replication and disease progression; however, our results
suggest that, unlike the effect noted for spontaneous clearance of
HCV, this host variant does not exert a strong influence on the
course of HBV infection.
In conclusion, a number of studies including the present have
clearly shown that Viet Nam is facing a huge burden of HBV
related liver disease. Thus, the enhancement of HBV screening
efforts in Viet Nam, in association with both vaccination and, if
economically possible, treatment for chronic infection, should be
prioritised to limit the future impact of serious liver disease.
Moreover, in HIV infected individuals, testing for HBV should be
implemented. Currently recommended treatment of coinfected
individuals with a tenofovir-based regimen would provide effective
therapy for both viruses and would be expected to prevent the
emergence of HBV drug resistance mutations.
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